These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 22539249)

  • 41. Pharmacokinetics and toxicity of intrathecal liposomal cytarabine in children and adolescents following age-adapted dosing.
    Peyrl A; Sauermann R; Chocholous M; Azizi AA; Jäger W; Höferl M; Slavc I
    Clin Pharmacokinet; 2014 Feb; 53(2):165-73. PubMed ID: 24129691
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy and safety of liposomal cytarabine in lymphoma patients with central nervous system involvement from lymphoma.
    Garcia-Marco JA; Panizo C; Garcia ES; Deben G; Alvarez-Larran A; Barca EG; Sancho JM; Penarrubia MJ; Garcia-Cerecedo T; Garcia Vela JA
    Cancer; 2009 May; 115(9):1892-8. PubMed ID: 19235254
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Intrathecal liposomal cytarabine: more friend than foe?
    Bhojwani D; Pui CH
    Leuk Lymphoma; 2008 Aug; 49(8):1427-30. PubMed ID: 18766957
    [No Abstract]   [Full Text] [Related]  

  • 44. [Chemotherapy of acute non-lymphocytic leukemia and non-hodgkin's lymphoma].
    Ogawa K
    Rinsho Ketsueki; 1989 Aug; 30(8):1222-6. PubMed ID: 2689680
    [No Abstract]   [Full Text] [Related]  

  • 45. Treatment of therapy-related acute myeloid leukemia occurring in elderly non-Hodgkin lymphoma patients with low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor.
    Tatetsu H; Matsuno F; Takatsu N; Miyake H; Hoshino K; Nosaka K; Horikawa K; Hata H; Mitsuya H; Asou N
    Leuk Res; 2009 Jan; 33(1):197-200. PubMed ID: 18472159
    [No Abstract]   [Full Text] [Related]  

  • 46. Liposomal Cytarabine Induces Less Neurocognitive Dysfunction Than Intrathecal Methotrexate in an Animal Model.
    Thomsen AM; Gulinello ME; Wen J; Schmiegelow K; Cole PD
    J Pediatr Hematol Oncol; 2018 Mar; 40(2):e91-e96. PubMed ID: 28654460
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [New agents in the treatment of leukemia and lymphoma].
    Yamada K
    Gan To Kagaku Ryoho; 1983 Apr; 10(4 Pt 2):1031-40. PubMed ID: 6347079
    [No Abstract]   [Full Text] [Related]  

  • 48. Cytarabine dose for acute myeloid leukemia.
    Löwenberg B; Pabst T; Vellenga E; van Putten W; Schouten HC; Graux C; Ferrant A; Sonneveld P; Biemond BJ; Gratwohl A; de Greef GE; Verdonck LF; Schaafsma MR; Gregor M; Theobald M; Schanz U; Maertens J; Ossenkoppele GJ;
    N Engl J Med; 2011 Mar; 364(11):1027-36. PubMed ID: 21410371
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Intrathecal chemotherapy treatment of neoplastic meningitis from solid tumors using liposomal cytarabine: experience at the Istituto Regina Elena di Roma].
    Pace A
    Tumori; 2007; 93(3):suppl 9-12. PubMed ID: 17679481
    [No Abstract]   [Full Text] [Related]  

  • 50. Spurious pleocytosis.
    Mathai S; Jones GL
    Blood; 2010 Aug; 116(5):678. PubMed ID: 20722103
    [No Abstract]   [Full Text] [Related]  

  • 51. Acyclovir bioavailability in patients with acute myelogenous leukemia treated with daunorubicin and cytarabine.
    Sitar DS; Aoki FY; Bow EJ
    J Clin Pharmacol; 2008 Aug; 48(8):995-8. PubMed ID: 18495946
    [No Abstract]   [Full Text] [Related]  

  • 52. Development of cytarabine prodrugs and delivery systems for leukemia treatment.
    Chhikara BS; Parang K
    Expert Opin Drug Deliv; 2010 Dec; 7(12):1399-414. PubMed ID: 20964588
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Hypersalivation as a leading symptom of neoplastic meningiosis in highly malignant non-Hodgkin's lymphoma].
    Heider A; Engels B; Hartmann-Klosterkötter U; Kress M; Niederle N
    Dtsch Med Wochenschr; 1993 Jan; 118(1-2):19-22. PubMed ID: 8420769
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Effects of small-dose cytarabine on the course of atheromatosis in over 60 years of age patients with acute myeloblastic leukemia (description of 2 cases)].
    Sokolov AN; Isaev VG; Savchenko VG
    Ter Arkh; 2002; 74(12):66-7. PubMed ID: 12577846
    [No Abstract]   [Full Text] [Related]  

  • 55. Cerebrospinal Fluid Drug Concentrations and Clinical Outcome of Patients with Neoplastic Meningitis Treated with Liposomal Cytarabine.
    Bohn JP; Reinstadler V; Pall G; Stockhammer G; Steurer M; Oberacher H; Wolf D
    Eur J Drug Metab Pharmacokinet; 2019 Dec; 44(6):845-851. PubMed ID: 31435852
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Rationale for the use of liposomal cytarabine in meningeal carcinomatosis].
    Boiardi A
    Tumori; 2007; 93(3):suppl 1-3. PubMed ID: 17679478
    [No Abstract]   [Full Text] [Related]  

  • 57. [A phase II study with high-dose cytarabine (NS-075) in adult patients with relapsed and refractory acute leukemia].
    Miyawaki S; Mizoguchi H; Tomonaga M; Kanamaru A; Tsukagoshi S; Nakamura T; Ohashi Y; Yoshida S; Ohno R
    Gan To Kagaku Ryoho; 1998 Dec; 25(14):2229-42. PubMed ID: 9881080
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Safety of liposomal cytarabine CNS prophylaxis in children, adolescent and young adult hematopoietic stem cell transplant recipients with acute leukemia and non-Hodgkin lymphoma.
    Hochberg J; Harrison L; Morris E; Militano O; Brand P; Fabricatore S; Wolownik K; Cairo MS
    Bone Marrow Transplant; 2016 Sep; 51(9):1249-52. PubMed ID: 27088378
    [No Abstract]   [Full Text] [Related]  

  • 59. Pharmacokinetics and safety of intrathecal liposomal cytarabine in children aged <3 years.
    Peyrl A; Sauermann R; Traunmueller F; Azizi AA; Gruber-Olipitz M; Gupper A; Slavc I
    Clin Pharmacokinet; 2009; 48(4):265-71. PubMed ID: 19492871
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cytarabine dose for acute myeloid leukemia.
    Mori J; Tsubokura M; Kami M
    N Engl J Med; 2011 Jun; 364(22):2166-7; author reply 2168-9. PubMed ID: 21631342
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.